Thomas John Charles sold 642 shares of Krystal Biotech, Inc. at $302.03 for −$194k on May 26, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
EVP, General Counsel
EVP, General Counsel
Filed May 27, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$193,903.26Shares × reported price
Shares traded
642Common Stock
Price per share
$302.03Reported price. Read footnotes for ranges.
% of reported position traded
100%This security and ownership context
Holdings after
0Direct
Trade date
May 26, 2026Sell
Filed
May 27, 2026, 5:17 PM ET1-day reporting delay
Accession
0002114900-26-000006Code S · Transaction 88388
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 642 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

KRYS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
KRYS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −11%1w ago −4.3%1d ago −2.3%
Returns since7d −1.6%30d +21%90d +15%180d1y

Footnotes in full

F1: The sales reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. The Rule 10b5-1 trading plan will terminate on December 31, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.